|
1. BIOLOGIE
|
|
|
|
1.4 BIOLOGIE - TECHNOS
|
|
|
|
3.2 PRÉVENTION - OBÉSITÉ
|
|
|
|
4.16 DÉP., DIAG. & PRONO. - PANCRÉAS
|
|
|
Molecular Characterisation of Non-functional Pancreatic Neuroendocrine Tumours [ESMO]
|
|
|
|
|
|
A research team composed from the investigators from US, Spain and the Netherlands published in the Nature Medicine a robust molecular stratification that provides insights into cell lineage correlates of non-functional pancreatic neuroendocrine tumours (pNETs), accurately predicts disease course and can inform postoperative clinical decisions.
|
|
|
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
|
5.12 IMMUNOTHÉRAPIES
|
|
|
|
5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
|
|
|
Celgene bags option on Nimbus' anticancer HPK1 inhibitor [Fierce Biotech]
|
|
|
|
|
|
Celgene and Nimbus’ interest in HPK1 reflects evidence that the protein kinase is involved the control of both T-cell proliferation and dendritic cell activation. Based on the current science, Nimbus thinks small-molecule inhibitors of HPK1 can have positive effects on the two key immune cells and immunosuppressive tumor microenvironments.
|
|
|
|
|
|
|
5.12.5 IMMUNOTHÉRAPIES - PHARMA
|
|
|
|
5.2 PHARMA
|
|
|
|
5.2.3 PHARMA - ÉCONOMIE
|
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
|
|
|
|
6. LUTTE CONTRE LES CANCERS
|
|
|
|
|
6.1 OBSERVATION
|
|
|
|
6.10.1 POLITIQUES (USA)
|
|
|
|
|
6.12 ETHIQUE
|
|
|
|
6.6 PUBLICATIONS
|
|
|
|
6.7.1 IA/BIOINFORMATIQUE
|
|
|
|
6.7.2 APPLIS
|
|
|
|
|
6.9 CONTROVERSES
|
|
|